For research use only. Not for use in humans.
Molecular Weight(MW): 455.34
Primaquine Diphosphate is a transmission-blocking anti-malarial clinically available, displaying a marked activity against gametocytes of all species of human malaria.
Purity & Quality Control
Choose Selective Anti-infection Inhibitors
|Description||Primaquine Diphosphate is a transmission-blocking anti-malarial clinically available, displaying a marked activity against gametocytes of all species of human malaria.|
Primaquine is still the only transmission-blocking anti-malarial clinically available, displaying a marked activity against gametocytes of all species of human malaria, including multi-resistant Plasmodium falciparum strains. Primaquine is also effective against all exoerythrocytic forms of the parasite and is used in conjunction with other anti-malarials for the treatment of vivax and ovale malaria. The exact mechanism by which Primaquine so effectively eliminates Plasmodium falciparum and gametocytes is still unknown, but it is thought that metabolism at the parasites’ mitochondria is impaired, eventually by interference with the ubiquinone function as an electron carrier in the respiratory chain. Another potential mechanism of anti-malarial action by Primaquine is the production of highly reactive metabolites that generate intracellular oxidative potentials. Primaquine is found to be an inhibitor of vesicular transport and blocks the calcium-release-activated current in rat megakaryocytes. Primaquine also acts on cardiac Na+ channels in isolated rat ventricular muscle and myocytes. Primaquine inhibits protein transport with IC50 of 50 μM, and inhibits the budding of vesicles from the donor membranes. PQ has a strong inhibitory effect on the recycling of endocytosed proteins to the plasma membrane. Primaquine is able to inhibit the potassium current by blockade of muscarinic receptors. Primaquine also inhibit human erythrocyte membrane acetylcholinesterase (AChE) with IC33 of 30 μM. Primaquine is a nitrite-reacting mutagen precursor where the secondary amino group plays a key role. 
|In vitro||DMSO||91 mg/mL (199.85 mM)|
|Water||91 mg/mL (199.85 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04073953||Not yet recruiting||Drug: RPQ|Drug: SPQ|Drug: Placebo||G6PD Deficiency||University of Mississippi Oxford|University of Colorado Denver|Southern Research||September 1 2019||Phase 1|
|NCT03352843||Recruiting||Drug: Primaquine||Malaria||Tropical Pesticides Research Institute Tanzania|European and Developing Countries Clinical Trials Partnership (EDCTP)||June 11 2019||Phase 4|
|NCT03934450||Completed||Drug: RPQ|Drug: SPQ|Drug: Primaquine Phosphate|Drug: Placebo||Malaria|Glucose 6 Phosphate Dehydrogenase Deficiency||University of Mississippi Oxford||August 17 2018||Phase 1|
|NCT02898779||Completed||Drug: Primaquine R-Primaquine S-Primaquine SR Primaquine||Malaria||University of Mississippi Oxford||May 1 2017||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.